The Role of Atomoxetine for Parkinson Disease–Related Executive Dysfunction: A Systematic Review

  title={The Role of Atomoxetine for Parkinson Disease–Related Executive Dysfunction: A Systematic Review},
  author={Carly B Warner and Andreina A Ottman and Jamie N. Brown},
  journal={Journal of Clinical Psychopharmacology},
Background Atomoxetine selectively inhibits the reuptake of norepinephrine. Given the noradrenergic system's role in executive function, pharmacotherapy options that affect norepinephrine are of particular clinical interest in Parkinson disease–related executive dysfunction. Objective The aim of this study was to assess the efficacy and safety of atomoxetine for Parkinson disease–related executive dysfunction. Methods MEDLINE (1946 to May 2018) and EMBASE (1947 to May 2018) were queried using… 

Atomoxetine Does Not Improve Complex Attention in Idiopathic Parkinson's Disease Patients with Cognitive Deficits: A Meta-Analysis

In idiopathic PD with MCI, atomoxetine does not improve complex attention and a deteriorative trend in the executive function was noted, and the estimated effect size was large and significant.

A Phase II Study Repurposing Atomoxetine for Neuroprotection in Mild Cognitive Impairment

A biomarker-driven phase II trial of atomoxetine, a clinically-approved NE transporter inhibitor, in subjects with mild cognitive impairment due to Alzheimers disease was safe, well tolerated, and achieved target engagement in prodromal Alzheimer disease.

The Effects of the Atypical Dopamine Uptake Inhibitor CE-158 on Extracellular Dopamine in the Nucleus Accumbens

Through this study, it was determined that injections of CE-158 significantly increased extracellular DA levels in the nucleus accumbens, which has been linked to increases in effort-based decision making and other aspects of motivation in humans suffering from MDD.

Neurobiology and clinical features of impulse control failure in Parkinson’s disease

Early screening for neuropsychiatric fluctuations, reduction of DA, fractionating levodopa dosage, education of patients and their relatives, are the key strategies for diagnosis and management of ICDs and related disorders.

Cognition Deficits in Parkinson's Disease: Mechanisms and Treatment

A description of cognitive decline in PD is focused on, the pathological mechanisms underlying cognition deficits in PD are expound emphatically, then a comprehensive overview of specific therapeutic strategies are given, and what fresh insights may bring new exciting prospect for the subfield are dissected.

Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects

Modafinil is a nonamphetamine nootropic drug with an increasingly therapeutic interest due to its different sites of action and behavioral effects in comparison to cocaine or amphetamine, and its psychotropic and cognitive effects are also attractive in several other pathologies and conditions that affect sleep structure, induce fatigue and lethargy, and impair cognitive abilities.

Clinical Trials In Parkinson's Disease

The main general limitation of neurotoxin-based models is that they do not replicate some characterizing features of PD pathology, such as the formation of Lewy body–like proteinaceous aggregates or the anatomical pattern of neurodegeneration, which also affects nondopaminergic brain regions.

Effects of Atomoxetine Hydrochloride on Regulation of Lifespan in Drosophila Model

It is reported that Atomoxetine (ATX) has sex-specific effect on prolonging the life span of female Drosophila melanogaster and further study indicated that ATX enhanced female resistance to heat stress and their vertical climbing ability, but it did decrease the number of eggs laid.



Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study

Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.

Improving Response Inhibition in Parkinson’s Disease with Atomoxetine

Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease

This interventional study provides Class II evidence that atomoxetine (target dosage = 80 mg/day) is not efficacious in improving clinically significant depression in PD, but was associated with improvement in global cognitive performance and daytime sleepiness.

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease

The hypothesis that atomoxetine may restore prefrontal networks related to executive functions is supported and it is suggested that task-free imaging can support translational pharmacological studies of new drug therapies and provide evidence for engagement of the relevant neurocognitive systems.

Executive dysfunction in Parkinson's disease: a review.

This review discusses how executive deficits relate to pathology in specific territories of the basal ganglia, consider the impact of dopaminergic treatment on executive function (EF) in this context, and review the changes in EFs with disease progression.

A Randomized Clinical Trial of Atomoxetine for Mild Cognitive Impairment in Parkinson's Disease

The authors hypothesized that atomoxetine would improve attention and executive functioning in patients with PD‐MCI.

Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder

The safety and efficacy of ATX in adults with ADHD are reviewed, including data in special populations, functional outcomes, as well as provider and patient real-world perceptions.

Targeting impulsivity in Parkinson’s disease using atomoxetine

Consistent with the presence of a longstanding noradrenergic deficit, atomoxetine improved stopping accuracy, and reduced reflection impulsivity during decision making in patients with Parkinson’s disease.

Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

There is insufficient evidence to support or refute the efficacy of DBS of the GPi or VIM nucleus of the thalamus in reducing off time, dyskinesia, or medication usage, or to improve motor function.

Comorbidity of the nonmotor symptoms of Parkinson's disease

It is revealed that the nonm motor symptoms of PD frequently occur together in the same patients, and increased comorbidity of the five nonmotor symptoms was associated with greater PD severity.